Targeted therapy with BRAF inhibitor Vemurafenib in relapse/refractory multisystem langerhans cell-retrospective analysis from a tertiary care center in India

Purva Kanvinde, Krishnan VP,Parth Ganatra,Archana Swami,Nitin Shah,Mukesh Desai,Bharat Agarwal,Minnie Bodhanwala,Sangeeta Mudaliar

Pediatric Hematology Oncology Journal（2021）

引用 0|浏览3

暂无评分

摘要

•Use of Vemurafenib in relapsed/refractory BRAFV600E LCH in India•Monotherapy of Vemurafenib in multisystem LCH•VMF with slow taper to maintain disease in remission and reduce financial burden

查看译文

关键词

Langerhans cell histiocytosis,BRAFV600E mutation,Vemurafenib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要